Compare Flagstar Bank NA (FLG) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs Smith & Nephew plc — how do they compare? Flagstar Bank NA trades at $15.43 (market cap $6.26B), while Smith & Nephew plc trades at $31.44 (market cap $12.81B). The key difference: Smith & Nephew plc is far larger — about 2× Flagstar Bank NA's market cap, and Smith & Nephew plc pays the higher dividend (2.54%). Which is the better fit depends on your goals.
| FLG | SNN | |
|---|---|---|
Market Cap | $6.26B | $12.81B |
Sector | Financials | Health |
52-Week High | $15.28 | $38.70 |
52-Week Low | $10.72 | $28.73 |
Dividend Yield | 0.27% | 2.54% |
Enterprise Value | — | $15.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Flagstar Bank (FLG) trades at $15.36, up 2.67% today, with a bullish technical signal from moving averages. The stock shows improving fundamentals, with two consecutive quarterly EPS beats and a positive Q1 2026 net income. The company is executing a turnaround, highlighted by a proprietary technology transformation and a credit rating upgrade. The price trades below the consensus target of $17.05, with a price-to-book ratio of 0.82 suggesting potential undervaluation.
The outlook is cautiously optimistic, supported by analyst consensus and recent profitability. Key opportunities include continued operational improvement and capital returns. Risks involve the ongoing turnaround execution, net negative cash flow, and sensitivity to interest rates. The stock presents a value proposition if the bank sustains its recovery trajectory.
Smith & Nephew (SNN) trades at $31.41, up 5.28% today, with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growth from $5.8B in 2024 to $6.2B projected for 2025 and net income margin expanding to 10.14%. Recent product launches in robotics and wound care, plus a $500M share buyback, highlight strategic execution. Analyst consensus is mixed with 27% buy ratings but 68% hold, reflecting cautious optimism amid earnings volatility where two of the last four quarters missed expectations.
Outlook: SNN's recovery trajectory and product innovation support long-term growth, but investor patience is needed due to earnings inconsistency and moderate debt levels. Key risks include competitive pressures in medtech and execution on guidance. The stock presents a value opportunity if operational improvements continue, trading at reasonable valuations (P/E 21.5, P/S 2.18) versus sector peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
